Drug Profile
PF 5161704
Alternative Names: PF-05161704; PF5161704Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 13 Aug 2010 Phase-I clinical trials in Type-2 diabetes mellitus (in healthy volunteers) in USA (PO)